Clinical study on prevention of no-reflow by early administration of intracoronary diltiazem through coronary artery during direct PCI
10.3969/j.issn.1006-5725.2014.23.043
- VernacularTitle:直接PCI中早期经冠脉给予地尔硫卓预防无复流的效果
- Author:
Dong SHI
;
Li HAN
;
Feng ZHANG
;
Ziwen REN
- Publication Type:Journal Article
- Keywords:
Angioplasty;
Coronary artery disease;
Incracoronary diltiazem;
Myocardial infarction;
No-reflow phenomenon
- From:
The Journal of Practical Medicine
2014;(23):3832-3834
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of the administration of intracoronary diltiazem before the occurrence of no-reflow during direct PCI. Mtthods One hundred and thirty four AMI patients hospitalized from June 2001 to November 2003 were selected as research objects. 60 patients with AMI received intracoronary diltiazem before the occurrence of no-reflow during direct PCI. 74 AMI patients did not receive intracoronary diltiazem and were enrolled as control subjects. Patients with refractory low blood pressure and complete atrioventricular block before PCI were excluded. Thrombolysis in Myocardial Infarction (TIMI) flow grade, corrected TIMI frame count (CTFC) were assessed during angiography, before and after PCI. Results The two groups had similar baseline. There were significant difference in post-PCI no reflow assessment (P = 0.04) and CTFC (P = 0.00). Conclusion Early administration of intracoronary diltiazem during direct PCI reduces the no reflow occurrence.
